Enlivex ENLV
NASDAQ ENLV
$1.04 -0.07 (-6.31%)
At close: Sep 9, 2026 · 4:00 PM EDT

Enlivex (ENLV) Income from Continuing Operations (2014 - 2025)

Enlivex (ENLV) posted Income from Continuing Operations of -$5.9 million for Q4 2025, down 129.21% on a QoQ basis from -$2.6 million in Q3 2025, and down 4.07% year-over-year from -$6.1 million in Q4 2024.

Analysis

Enlivex (ENLV) Income from Continuing Operations (2014 - 2025) Analysis & Trends

Enlivex has reported Income from Continuing Operations for 12 years, with the latest figure at -$5.9 million in Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 4.07% year-over-year to -$5.9 million in Q4 2025; TTM through Dec 2025 was -$15.0 million, a 5.41% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 10787.03% from the prior year.
  • Income from Continuing Operations was -$5.9 million for Q4 2025 at Enlivex, down from -$2.6 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $2.1 million in Q2 2021, with the low at -$10.3 million in Q4 2023.
  • Average Income from Continuing Operations over 5 years is -$4.7 million, with a median of -$5.6 million recorded in 2023.
  • The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations surged 277.53% in 2021, then slumped 762.43% in 2022.
  • Over 5 years, Income from Continuing Operations stood at -$7.8 million in 2021, then decreased by 0.4% to -$7.8 million in 2022, then sank by 31.74% to -$10.3 million in 2023, then soared by 45.51% to -$5.6 million in 2024, then fell by 4.07% to -$5.9 million in 2025.
  • The last three Income from Continuing Operations figures came in at -$5.9 million (Q4 2025), -$2.6 million (Q3 2025), and -$3.1 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 601.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -290.61 Mn
10 Enlivex 3.17 Mn -2.59 Mn - -5.86 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -5.86 Mn
Sep 30, 2025 -2.56 Mn
Jun 30, 2025 -3.08 Mn
Mar 31, 2025 -3.53 Mn
Dec 31, 2024 -5.63 Mn
Sep 30, 2024 -3.12 Mn
Jun 30, 2024 -2.99 Mn
Mar 31, 2024 -4.15 Mn
Dec 31, 2023 -10.34 Mn
Sep 30, 2023 -5.63 Mn
Jun 30, 2023 -6.65 Mn
Mar 31, 2023 -6.78 Mn
Dec 31, 2022 -7.85 Mn
Sep 30, 2022 -5.68 Mn
Jun 30, 2022 -5.87 Mn
Mar 31, 2022 -6.40 Mn
Dec 31, 2021 -7.81 Mn
Sep 30, 2021 857,000.00
Jun 30, 2021 2.06 Mn
Mar 31, 2021 -2.79 Mn